|
Boston, MA, May 12, 2003 – The Leukemia & Lymphoma Society celebrated the Journey of Hope donor reception at the Boston College Club last Thursday night. Donors gathered together for a wine and hors d'oeuvres reception followed by a program which included an awards presentation. Keynote speakers included Dr. David Avigan, Director of the Hematologic Malignancy/Bone Marrow Transplantation Program at Beth Israel Deaconess Medical Center and Dr. Alan Kinniburgh, Vice President of Research at The Leukemia & Lymphoma Society. Dr. Avigan spoke about his work with cancer vaccines and his current clinical trials. Dr. Kinniburgh gave updates in research and history of the Society.
One of the highlights of the program was the presentation of the deVilliers awards. The deVilliers awards were established for people who are making a significant financial commitment both now and/or in the future through their estate plan. The award is named after Robert deVilliers, son of the founders of the Society, who passed away from leukemia at the age of 16. The deVilliers awards are significant in acknowledging the supporters who play such a significant role in advancing our mission. The Society had the pleasure of honoring Haemonetics Corporation at this reception for their $20,000 research gift. Haemonetics chose to partially fund Dr. Ramesh Shivdasani at the Dana-Farber Cancer Institute this year. Dr. Shivdasani is currently receiving a Scholar research grant from The Leukemia & Lymphoma Society, which this gift will help to support. Dr. Shivdasani's work involves molecular regulation of platelet development. His work is relevant to AML, ALL, CML, multiple myeloma and other myeloid diseases. Haemonetics Corporation designs and manufacturers automated blood-processing systems. The Leukemia & Lymphoma Society is pleased to be receiving continued support from Haemonetics in research and for special events.
The Leukemia & Lymphoma Society, based in White Plains, NY, is the fastest-growing voluntary health organization with a nationwide presence. The Society's mission is to cure leukemia, lymphoma, Hodgkin's disease and myeloma and to improve the quality of life of patients and their families. Since its founding in 1949, the Society has provided more than $320 million for research specifically targeting blood-related cancers. For additional information, contact the Society at (800) 955-4572 or visit www.leukemia-lymphoma.org.
Haemonetics is a global company engaged in the design, manufacture and worldwide marketing of automated blood processing systems. These systems address important medical markets: surgical blood salvage, blood component collections and plasma collections. To learn more about Haemonetics' products and markets, visit the Company's web site at http://www.haemonetics.com.
This release contains forward looking statements that involve risks and uncertainties, including technological advances in the medical field, product demand, market acceptance, regulatory uncertainties, the effect of economic conditions, the impact of competitive products and pricing, blood product reimbursement policies and practices, foreign currency exchange rates and other risks detailed in the Company's filings with the Securities and Exchange Commission. The forward looking statements are based on estimates and assumptions made by management of the Company and are believed to be reasonable, though are inherently uncertain and difficult to predict. Actual results and experience could differ materially from the forward looking statements.
###
|
